Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma Journal Article


Authors: Patel, P. H.; Kondagunta, G. V.; Schwartz, L.; Ishill, N.; Bacik, J.; Deluca, J.; Russo, P.; Motzer, R. J.
Article Title: Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma
Abstract: Lenalidomide (CC-5013) is a structural derivative of thalidomide, with antiangiogenic and immunomodulatory effects. Fourteen patients with metastatic renal cell carcinoma (RCC) were enrolled on a phase 2 trial of lenalidomide administered orally at 25 mg daily for 21 days followed by a rest period of 7 days. The best response was stable disease in eight patients (57%) of the 14 evaluable patients. Toxicities included fatigue, hyperglycemia, dyspnea, and myelosuppression with decreased hemoglobin, lymphopenia, and neutropenia. Lenalidomide is tolerable, but no objective responses were observed in this clinical trial. © 2007 Springer Science+Business Media, LLC.
Keywords: adult; cancer survival; clinical article; treatment outcome; aged; middle aged; lenalidomide; thalidomide; clinical trial; constipation; drug tolerability; fatigue; neutropenia; drug dose reduction; drug efficacy; hypertension; monotherapy; side effect; treatment duration; antineoplastic agents; cancer patient; metastasis; multiple cycle treatment; phase 2 clinical trial; anemia; bone marrow suppression; blood toxicity; dehydration; hemoglobin blood level; hypercalcemia; patient assessment; renal cell carcinoma; kidney carcinoma; kidney neoplasms; dyspnea; hyperglycemia; lymphocytopenia; carcinoma, renal cell; drug response; neoplasm metastasis; administration, oral; phase ii; cc-5013
Journal Title: Investigational New Drugs
Volume: 26
Issue: 3
ISSN: 0167-6997
Publisher: Springer  
Date Published: 2008-06-01
Start Page: 273
End Page: 276
Language: English
DOI: 10.1007/s10637-007-9107-y
PUBMED: 18161005
PROVIDER: scopus
DOI/URL:
Notes: --- - "Cited By (since 1996): 6" - "Export Date: 17 November 2011" - "CODEN: INNDD" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Paul Russo
    581 Russo
  2. Robert Motzer
    1243 Motzer
  3. Lawrence H Schwartz
    307 Schwartz
  4. Premal Patel
    9 Patel
  5. Nicole Marie Leoce
    86 Leoce
  6. John Vito K Deluca
    8 Deluca
  7. Jennifer M Bacik
    46 Bacik